Emerging drug profile: CPX-351 (vyxeos) in AML

Mansour Alfayez,Hagop M. Kantarjian,Tapan M. Kadia,Farhad Ravandi-Kashani,Naval Daver

Emerging drug profile: CPX-351 (vyxeos) in AML

2019

Mansour Alfayez
Hagop M. Kantarjian
Tapan M. Kadia
Farhad Ravandi-Kashani
Naval Daver

AbstractFor decades, the standard induction for patients with acute myeloid leukemia (AML) has been the combination of cytarabine with anthracycline (7 + 3 regimen). In August 2017 the US FDA appro...

Keywords:

Cytarabine
Diabetes mellitus
Anthracycline
Oncology
Immunology
Medicine
Regimen
Drug
Internal medicine
Myeloid leukemia
therapy related

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations